CHRS
0.82+0.05 +6.23%Past year
Loading chart…
Loading financials…
Company snapshot
- Ticker
- CHRS
- Exchange
- NGM
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $126.32M
- Employees
- 144
- Currency
- USD
- Website
- https://www.coherus.com
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human…
Latest coverage
- Coherus Oncology: 3 Key Takeaways for Long-Term Investors
November 10, 2026